Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results

      Astrana Health Logo (PRNewsfoto/Astrana Health, Inc.)

      News provided by

      Astrana Health, Inc.

      Mar 02, 2026, 07:00 ET

      Share this article

      Share this article


      Company to Host Conference Call on Monday, March 2, 2026, at 5:30 a.m. PT/8:30 a.m. ET

      • Reports total revenue for the year ended of $3,181.8 million, up 56% year-over-year, and at the higher end of guidance
      • Reports adjusted EBITDA for the year ended of $205.4 million and free cash flow(1) of $104.5 million

      ALHAMBRA, Calif., March 2, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading physician-centric, technology-powered, risk-bearing healthcare management company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the fourth quarter and year ended December 31, 2025.

      "Astrana delivered record revenue, adjusted EBITDA, and free cash flow in 2025, demonstrating the strength and predictability of our fully delegated, payer-agnostic care model and AI-enabled technology platform in a dynamic operating environment," said Brandon Sim, President and Chief Executive Officer of Astrana Health. "Our disciplined approach to risk, strong physician alignment, and technology-enabled clinical infrastructure drove consistent performance while creating measurable value for patients through improved outcomes, greater access, and lower total cost of care. As we move through 2026, with Prospect Health integration ahead of schedule, we are confident in our ability to deliver on guidance that reflects approximately 24% revenue growth and 29% adjusted EBITDA growth at the midpoint."

      Financial Highlights for Year Ended December 31, 2025:

      All comparisons are to the year ended December 31, 2024 unless otherwise stated.

      • Total revenue of $3,181.8 million, up 56% from $2,034.5 million
      • Care Partners revenue of $3,022.6 million, up 55% from $1,949.0 million
      • Net income attributable to Astrana of $22.5 million
      • Earnings per share ("EPS") - diluted of $0.46
      • Adjusted EBITDA(2) of $205.4 million, up 21% from $170.4 million
      • Adjusted EPS - diluted(3) of $2.20

      Financial Highlights for the Fourth Quarter 2025:

      All comparisons are to the quarter ended December 31, 2024 unless otherwise stated.

      • Total revenue of $950.5 million, up 43% from $665.2 million
      • Care Partners revenue of $892.5 million up 38% from $647.7 million
      • Net income attributable to Astrana of $6.0 million
      • EPS - diluted of $0.12
      • Adjusted EBITDA(2) of $52.5 million, up 50% from $35.0 million
      • Adjusted EPS - diluted(3) of $0.54

      (1) 

      See reconciliation provided with the condensed consolidated statements of cash flow and "Use of Non-GAAP Financial Measures" below for additional information.

      (2)

      See "Reconciliation of Net Income (Loss) to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted" and "Use of Non-GAAP Financial Measures" below for additional information.

      (3)

      See "Reconciliation of Net Income (Loss) to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information.

      Update on Annual Report Filing

      The Company will be filing a Form 12b-25 with the Securities and Exchange Commission to extend the deadline for its Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K") due to a material weakness in internal control over financial reporting, which is expected to relate to, but may not be limited to, the Company's acquisition and purchase accounting processes. This matter relates to the timing and documentation of certain control procedures and does not reflect any material misstatement of the Company's financial results, nor does it result in any restatements of historical periods. The Company currently expects to file the 2025 Form 10-K within the fifteen-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended, and is making targeted investments in our accounting organization to accelerate remediation.

      Stock Repurchase Program

      The Board of Directors has increased the maximum aggregate amount of shares of the Company's common stock that may be purchased under the Company's existing share repurchase program from $50 million to $100 million. Repurchases may be made through a variety of methods, which could include open market purchases, accelerated share repurchase transactions, negotiated block transactions, 10b5-1 plans, other transactions that may be structured through investment banking institutions or privately negotiated, or a combination of the foregoing. The amount and timing of future repurchases, if any, may vary depending on management's assessment of the intrinsic value of the Company's common stock, the market price of the Company's common stock, general market and economic conditions, available liquidity, compliance with the Company's debt and other agreements, applicable legal requirements, the level of operating, financing and other investing activities, and other considerations. The repurchase authorization does not have an expiration date.

      The Company is not obligated to purchase any shares under the repurchase program, and the program may be suspended, modified, or discontinued at any time without prior notice. During the three months ended December 31, 2025, 633,844 shares were repurchased under the Company's share repurchase plan. As of December 31, 2025, $35.9 million remained available under the repurchase plan. The Company may determine to continue to make repurchases under the program following the filing of the Form 10-K for the year ended December 31, 2025.

      Segment Results for Year Ended December 31, 2025:

      All comparisons are to the year ended December 31, 2024 unless otherwise stated.



      Year Ended
      December 31,
      2025













      (in thousands)


      Care
      Partners



      Care
      Delivery



      Care
      Enablement



      Intersegment
      Elimination



      Corporate
      Costs



      Consolidated
      Total


      Total revenues


      $

      3,022,602



      $

      250,742



      $

      246,660



      $

      (338,235)



      $

      —



      $

      3,181,769


      % change vs. prior year



      55

      %



      83

      %



      59

      %





























      Cost of services



      2,615,578




      203,895




      148,629




      (127,863)




      —




      2,840,239


      General and administrative



      217,656




      45,004




      52,130




      (210,400)




      112,866




      217,256


      Depreciation and amortization



      34,401




      3,858




      6,185




      —




      1,305




      45,749


      Total expenses



      2,867,635




      252,757




      206,944




      (338,263)




      114,171




      3,103,244





















      Income (loss) from operations


      $

      154,967



      $

      (2,015)



      $

      39,716



      $

      28


      (1)

      $

      (114,171)



      $

      78,525


      % change vs. prior year



      10

      %


      *




      117

      %





































      (1)

      Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.

      *

      Percentage change of over 500%

      2026 Guidance:

      Astrana is providing the following guidance for total revenue and Adjusted EBITDA for the three months ending March 31, 2026 and the year ending December 31, 2026 based on the Company's existing business, current view of existing market conditions, and assumptions.

      ($ in millions)


      Three Months Ending
      March 31, 2026



      Year Ending
      December 31, 2026




      Guidance Range



      Guidance Range




      Low



      High



      Low



      High


      Total revenue


      $

      900



      $

      1,000



      $

      3,800



      $

      4,100


      Adjusted EBITDA


      $

      60



      $

      70



      $

      250



      $

      280


      See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.

      Conference Call and Webcast Information:

      Astrana will host a conference call at 5:30 a.m. PT/8:30 a.m. ET today (Monday, March 2, 2026), during which management will discuss the results of the fourth quarter and year end December 31, 2025. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

      U.S. & Canada (Toll-Free):

      +1 (877) 858-9810

      International (Toll):

      +1 (201) 689-8517

      The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=CAALhYDU

      An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.

      Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

      Note About Consolidated Entities

      The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Noncontrolling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income attributable to noncontrolling interests is disclosed in the Company's consolidated statements of income.

      About Astrana Health, Inc.

      Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.

      Today, Astrana supports more than 20,000 providers and over 1.6 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.

      Forward-Looking Statements

      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the year ending  December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the Company's expectations regarding the timing of filing its 2025 Form 10-K, the expected material weakness in internal control over financial reporting and the Company's ability to remediate any such material weakness in a timely manner, the consistency of the financial statements in the 2025 Form 10-K with the financial information in this earnings release and the completion of matters necessary to permit filing by the extension deadline. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's last Annual Report on Form 10-K and any subsequent quarterly reports on Form 10-Q filed with the SEC. Any forward-looking statements made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

      FOR MORE INFORMATION, PLEASE CONTACT:

      Investor Relations

      Carolyne Sohn
      [email protected]

      ASTRANA HEALTH, INC.

      CONSOLIDATED BALANCE SHEETS

      (in thousands, except share and per share data)




      December 31,
      2025



      December 31,
      2024


      Assets














      Current assets







      Cash and cash equivalents


      $

      429,474



      $

      288,455


      Receivables, net (including amounts with related parties)



      374,465




      275,990


      Income taxes receivable



      1,799




      19,316


      Other receivables



      26,385




      29,496


      Prepaid expenses and other current assets



      26,264




      25,239


      Loans receivable



      4,926




      —









      Total current assets



      863,313




      638,496









      Non-current assets







      Property and equipment, net



      58,693




      14,274


      Intangible assets, net



      270,968




      118,179


      Goodwill



      863,944




      419,253


      Income taxes receivable, non-current



      26,220




      15,943


      Loans receivable, non-current



      48,724




      51,266


      Investments in other entities – equity method



      25,637




      39,319


      Investments in privately held entities



      2,896




      8,896


      Operating lease right-of-use assets



      35,738




      32,601


      Other assets



      22,528




      16,667









      Total non-current assets



      1,355,348




      716,398









      Total assets (1)


      $

      2,218,661



      $

      1,354,894









      Liabilities, Mezzanine Deficit, and Stockholders' Equity














      Current liabilities







      Accounts payable and accrued expenses


      $

      195,912



      $

      106,142


      Fiduciary accounts payable



      3,524




      8,223


      Medical liabilities



      335,705




      209,039


      Operating lease liabilities



      7,809




      5,350


      Current portion of long-term debt



      47,865




      9,375


      Other liabilities



      24,458




      27,479









      Total current liabilities



      615,273




      365,608









      Non-current liabilities







      Deferred tax liability



      5,491




      4,555


      Operating lease liabilities, net of current portion



      31,552




      30,654


      Long-term debt, net of current portion and deferred financing costs



      990,904




      425,299


      Other long-term liabilities



      17,107




      14,610









      Total non-current liabilities



      1,045,054




      475,118









      Total liabilities (1)


      $

      1,660,327



      $

      840,726









      Mezzanine deficit







      Non-controlling interest in Allied Physicians of California, a Professional
         Medical Corporation ("APC")



      (234,962)




      (202,558)









      Stockholders' equity







      Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, and zero shares issued and outstanding as of December 31, 2025 and December 31, 2024



      —




      —


      Common stock, $0.001 par value per share; 100,000,000 shares authorized, 48,885,358 and 47,929,872 shares issued and outstanding, excluding 10,571,011 and 10,603,849 treasury shares, as of December 31, 2025 and December 31, 2024, respectively



      49




      48


      Additional paid-in capital



      470,863




      426,389


      Retained earnings



      308,379




      286,283


      Total stockholders' equity



      779,291




      712,720









      Non-controlling interest



      14,005




      4,006









      Total equity



      793,296




      716,726









      Total liabilities, mezzanine deficit, and stockholders' equity


      $

      2,218,661



      $

      1,354,894




      (1)

      The Company's consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company's consolidated VIEs totaling $1,276.5 million and $712.3 million as of December 31, 2025 and December 31, 2024, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $376.0 million and $207.9 million as of December 31, 2025 and December 31, 2024, respectively. These VIE balances do not include $152.2 million of investment in affiliates and $58.3 million of amounts due from affiliates as of December 31, 2025, and $224.9 million of investment in affiliates and $48.1 million of amounts due to affiliates as of December 31, 2024, as these are eliminated upon consolidation and not presented within the consolidated balance sheets.

      ASTRANA HEALTH, INC.

      CONSOLIDATED STATEMENTS OF INCOME

      (in thousands, except share and per share data)




      Three Months Ended
      December 31,



      Years Ended
      December 31,




      2025



      2024



      2025



      2024


      Revenue













      Capitation, net


      $

      862,814



      $

      616,900



      $

      2,924,265



      $

      1,856,785


      Risk pool settlements and incentives



      25,508




      28,660




      86,199




      86,224


      Management fee income



      10,290




      5,550




      30,394




      13,979


      Fee-for-service, net



      39,787




      7,743




      112,635




      62,331


      Other revenue



      12,127




      6,356




      28,276




      15,221















      Total revenue



      950,526




      665,209




      3,181,769




      2,034,540















      Operating expenses













      Cost of services, excluding depreciation and amortization



      855,483




      614,730




      2,840,239




      1,763,152


      General and administrative expenses



      60,247




      41,633




      217,256




      154,111


      Depreciation and amortization



      16,401




      8,126




      45,749




      27,927















      Total expenses



      932,131




      664,489




      3,103,244




      1,945,190















      Income from operations



      18,395




      720




      78,525




      89,350















      Other expense













      Income from equity method investments



      1,176




      1,564




      1,708




      4,451


      Interest expense



      (17,520)




      (8,069)




      (49,928)




      (33,097)


      Interest income



      3,987




      3,221




      12,157




      14,508


      Unrealized gain (loss) on investments



      769




      316




      (68)




      731


      Other income (loss)



      699




      353




      (2,788)




      4,875















      Total other expense, net



      (10,889)




      (2,615)




      (38,919)




      (8,532)















      Income (loss) before provision for income taxes



      7,506




      (1,895)




      39,606




      80,818















      Provision for income taxes



      944




      5,882




      15,530




      30,886















      Net income (loss)



      6,562




      (7,777)




      24,076




      49,932















      Net income (loss) attributable to noncontrolling interests



      563




      (826)




      1,589




      6,783















      Net income (loss) attributable to Astrana Health, Inc.


      $

      5,999



      $

      (6,951)



      $

      22,487



      $

      43,149















      Earnings (loss) per share – basic


      $

      0.12



      $

      (0.15)



      $

      0.46



      $

      0.91















      Earnings (loss) per share – diluted


      $

      0.12



      $

      (0.15)



      $

      0.46



      $

      0.90















      Weighted average shares of common stock outstanding – basic



      49,230,904




      47,823,360




      49,075,727




      47,597,295















      Weighted average shares of common stock outstanding – diluted



      49,527,521




      47,823,360




      49,369,685




      47,974,334


      ASTRANA HEALTH, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

      (in thousands)




      Years ended December 31,




      2025



      2024


      Cash flows from operating activities







      Net income


      $

      24,076



      $

      49,932


      Adjustments to reconcile net income to net cash provided by operating activities:







      Depreciation and amortization



      45,749




      27,927


      Amortization of debt issuance cost



      4,050




      1,828


      Share-based compensation



      38,601




      34,536


      Non-cash lease expense



      6,647




      5,278


      Deferred tax



      (4,287)




      (4,249)


      Change in fair value of contingent consideration liabilities



      5,166




      3,526


      Other



      (2,307)




      (2,967)


      Changes in operating assets and liabilities, net of business combinations



      (3,098)




      (63,613)


      Net cash provided by operating activities



      114,597




      52,198









      Cash flows from investing activities







      Payments for business and asset acquisition, net of cash acquired



      (548,604)




      (146,260)


      Purchases of investments – equity method



      —




      (5,968)


      Purchase of call option issued in conjunction with equity method investment



      —




      (3,907)


      Issuance of loans receivable



      (1,708)




      (26,000)


      Purchases of property and equipment



      (10,106)




      (8,031)


      Proceeds from sale of equity method investment



      15,100




      —


      Other



      6,319




      (2,229)


      Net cash used in investing activities



      (538,999)




      (192,395)









      Cash flows from financing activities







      Dividends paid



      (7,885)




      (4,036)


      Repayments on debt



      (495,289)




      (18,500)


      Borrowings on debt



      1,119,300




      171,875


      Taxes paid from net share settlement of restricted stock



      (6,169)




      (4,662)


      Repurchase of treasury shares



      (15,429)




      (937)


      Deferred financing cost



      (19,205)




      —


      Payment of financing obligation



      —




      (8,542)


      Payment of contingent consideration liabilities



      (8,284)




      (518)


      Other



      2,307




      466


      Net cash provided by financing activities



      569,346




      135,146









      Net increase (decrease) in cash, cash equivalents, and restricted cash



      144,944




      (5,051)









      Cash, cash equivalents, and restricted cash, beginning of year



      289,101




      294,152









      Cash, cash equivalents, and restricted cash, end of year


      $

      434,045



      $

      289,101









      Supplemental disclosures of cash flow information







      Cash paid for income taxes


      (1)



      $

      43,936


      Cash paid for interest


      $

      45,767



      $

      30,419









      Supplemental disclosures of non-cash investing and financing
         activities







      Right-of-use assets obtained in exchange for operating lease liabilities


      $

      11,875



      $

      14,117


      Common stock issued in business combination


      $

      —



      $

      21,952


      Common stock issued for contingent consideration payment


      $

      2,600



      $

      4,023


      Acquisition of business through loan conversion


      $

      —



      $

      5,175


      Draw on letter of credit through Revolver Loan


      $

      —



      $

      4,732


      Elimination of note payable upon consolidation


      $

      9,488



      $

      —


      Reclass of investment – Third Way Health


      $

      6,000



      $

      —


      Repurchase of treasury shares outstanding payable


      $

      922



      $

      —


      Dividend paid in form of stock


      $

      21,935



      $

      —




      (1)

      Following the adoption of ASC 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures", cash paid for income taxes is presented net of tax refunds, for the year ended December 31, 2025 and prospectively, under Item 8 of the Company's Annual Report on Form 10-K.

      The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):



      December 31,




      2025



      2024


      Cash and cash equivalents


      $

      429,474



      $

      288,455


      Restricted cash (1)



      4,571




      646


      Total cash, cash equivalents and restricted cash shown in the statement of cash flows


      $

      434,045



      $

      289,101




      (1)

      Restricted cash is included in other assets on the consolidated balance sheets.

      The following table provides a reconciliation of net cash provided by operating activities to free cash flow for the years ended December 31, 2025 and 2024 (in thousands):

      Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow


      December 31,




      2025



      2024


      Net cash provided by operating activities


      $

      114,597



      $

      52,198


      Cash used in purchases of property and equipment



      (10,106)




      (8,031)


      Free cash flow


      $

      104,491



      $

      44,167


      Reconciliation of Net Income (Loss) to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin

      Set forth below are reconciliations of net income (loss) to EBITDA and Adjusted EBITDA as well as the reconciliation to Adjusted EBITDA margin for the three months and years ended December 31, 2025 and 2024. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.



      Three Months Ended
      December 31,



      Years Ended
      December 31,



      (in thousands)


      2025



      2024



      2025



      2024



      Net income (loss)


      $

      6,562



      $

      (7,777)



      $

      24,076



      $

      49,932



      Interest expense



      17,520




      8,069




      49,928




      33,097



      Interest income



      (3,987)




      (3,221)




      (12,157)




      (14,508)



      Provision for income taxes



      944




      5,882




      15,530




      30,886



      Depreciation and amortization



      16,401




      8,126




      45,749




      27,927



      EBITDA



      37,440




      11,079




      123,126




      127,334

















      Income from equity method investments



      (1,176)




      (1,564)




      (1,708)




      (4,451)



      Other, net



      4,808


      (1)


      10,288


      (2)


      45,405


      (3)


      12,951


      (4)

      Stock-based compensation



      11,382




      15,235




      38,601




      34,536



      Adjusted EBITDA


      $

      52,454



      $

      35,038



      $

      205,424



      $

      170,370

















      Total revenue


      $

      950,526



      $

      665,209



      $

      3,181,769



      $

      2,034,540

















      Adjusted EBITDA margin



      6

      %



      5

      %



      6

      %



      8

      %




      (1)

      Other, net, for the three months ended December 31, 2025 relates to $2.3 million for transaction and integration costs primarily for the acquisition of Prospect, certain costs and final settlement for some of our acquisitions, and severance fees incurred, partially offset by employer retention tax credits related to COVID-19 relief.

      (2)

      Other, net for the three months ended December 31, 2024 relates to transaction costs incurred for our investments, to anticipated recoveries from one time losses relating to third party payer payments associated with the Collaborative Health Systems, LLC ("CHS") transaction, and non-cash change in the fair value of our call option.

      (3)

      Other, net, for the year ended December 31, 2025, relates to $13.0 million for a legal matter with a provider associated with CFC HP, $25.9 million for transaction and integration costs primarily for the acquisition of Prospect, debt issuance costs incurred in connection with our Second Amended and Restated Credit Facility, certain costs and final settlement for some of our acquisitions, and severance fees incurred, partially offset by employer retention tax credits related to COVID-19 relief.

      (4)

      Other, net for the year ended December 31, 2024 relates to transaction costs incurred for our investments and tax restructuring fees, anticipated recoveries from one-time losses relating to third party payor payments associated with the CHS transaction, a financial guarantee via a letter of credit that we provided in support of two local provider-led ACOs, non-cash gain on debt extinguishment related to one of our promissory note payables, non-cash realized loss from the sale of one of our marketable equity securities, non-cash changes related to change in the fair value of our call option, non-cash change in the fair value of our financing obligation to purchase the remaining equity interests in one our investments, non-cash changes in the fair value of our contingent liabilities, non-cash changes in the fair value of the Company's Collar Agreement, and reimbursement from a related party of the Company for taxes associated with the Excluded Assets spin-off

      Reconciliation of Net Income (Loss) to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted

      Set forth below are reconciliations of net income (loss) to adjusted net income attributable to Astrana as well as the reconciliation to adjusted EPS - diluted for the three months and years ended December 31, 2025 and 2024.



      Three Months Ended
      December 31,



      Years Ended
      December 31,



      (in thousands, except for share and per share data)


      2025



      2024



      2025



      2024



      Net income (loss)


      $

      6,562



      $

      (7,777)



      $

      24,076



      $

      49,932



      Income from equity method investments



      (1,176)




      (1,564)




      (1,708)




      (4,451)



      Other, net (1)



      4,808




      10,288




      45,405




      12,951



      Stock-based compensation



      11,382




      15,235




      38,601




      34,536



      Amortization of intangibles



      14,128




      7,567




      40,747




      25,608



      Tax adjustments



      (5,485)


      (2)


      (5,411)


      (3)


      (25,337)


      (2)


      (13,902)


      (3)

      Adjusted non-controlling interest



      (3,300)


      (4)


      (2,186)


      (5)


      (13,203)


      (4)


      (11,629)


      (5)

      Adjusted net income attributable to Astrana Health, Inc.


      $

      26,919



      $

      16,152



      $

      108,581



      $

      93,045

















      Weighted average shares of common stock outstanding – diluted



      49,527,521




      47,823,360




      49,369,685




      47,974,334

















      Adjusted earnings per share - diluted


      $

      0.54



      $

      0.34



      $

      2.20



      $

      1.94





      (1)

      The components of other, net, as set forth in the table above, are described in the footnotes to the table under "Reconciliation of Net Income (Loss) to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin". Please see the footnotes for additional information.

      (2)

      Tax adjustments for the three months and year ended December 31, 2025, includes the tax effect for, at a 27.1% statutory blended tax rate, the adjustments made to net income of $7.9 million and $33.3 million, respectively, partially offset by 162(m) impact of $2.4 million and $7.5 million, respectively.

      (3)

      Tax adjustments for the three months and year ended December 31, 2024, includes the tax effect for, at a 28.0% statutory blended tax rate, the adjustments made to net (loss) income of $8.8 million and $19.2 million, respectively, partially offset by 162(m) impact of $3.4 million and $5.3 million, respectively.

      (4)

      Includes net income attributable to non-controlling interests ("NCI") of $0.6 million and $1.6 million, respectively, and adjustments attributable to NCI of $2.7 million and $11.6 million, respectively, for the three months and year ended December 31, 2025.

      (5)

      Includes net loss and income, respectively, attributable to NCI of $0.8 million and $6.8 million, respectively, and adjustments attributable to NCI of $3.0 million and $4.8 million, respectively, for the three months and year ended December 31, 2024.

      Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA



      Year Ending
      December 31, 2026




      Guidance Range


      (in thousands)


      Low



      High


      Net income


      $

      54,000



      $

      74,000


      Interest expense



      51,000




      55,000


      Provision for income taxes



      38,000




      44,000


      Depreciation and amortization



      65,000




      65,000


      EBITDA



      208,000




      238,000









      Income from equity method investments



      (4,000)




      (4,000)


      Other, net



      7,000




      7,000


      Stock-based compensation



      39,000




      39,000


      Adjusted EBITDA


      $

      250,000



      $

      280,000


      The Company has not provided a quantitative reconciliation of EBITDA and Adjusted EBITDA for the three months ending March 31, 2026 to the most comparable GAAP measure on a forward-looking basis within this press release because the Company is unable, without unreasonable efforts, to provide reconciling information with respect to certain line items that cannot be calculated for the three month period. These items, which could materially affect the computation of forward-looking GAAP net income, are inherently uncertain and depend on various factors, some of which are outside of the Company's control.

      Use of Non-GAAP Financial Measures

      This press release contains the non-GAAP financial measures EBITDA, Adjusted EBITDA, adjusted net income attributable to Astrana, and adjusted EPS - diluted, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income (loss). This press release also contains the non-GAAP financial measure free cash flow, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net cash provided by operating activities. These measures are not in accordance with, or alternatives to GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA, Adjusted EPS – diluted, and free cash flow as supplemental performance measures of our operations, for financial and operational decision-making, and as supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest expense, interest income, income taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, and stock-based compensation. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue. Adjusted net income attributable to Astrana is calculated as net income (loss), excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, amortization of intangibles, certain tax adjustments, and amounts related to non-controlling interest. The Company defines adjusted EPS - diluted as adjusted net income attributable to Astrana over weighted average shares of common stock outstanding - diluted. The Company defines free cash flow as net cash provided by operating activities and cash used in purchases of property and equipment.

      The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate EBITDA, Adjusted EBITDA, adjusted net income attributable to Astrana, adjusted EPS – diluted, and free cash flow differently, limiting the usefulness of these measures for comparative purposes. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.

      SOURCE Astrana Health, Inc.

      Modal title

      Also from this source

      Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement

      Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement

      Foothill Regional Medical Center, part of Astrana Health, Inc. (NASDAQ: ASTH), earned multiple national honors from Healthgrades, the leading...

      Astrana Health, Inc. Reports Third Quarter 2026 Results

      Astrana Health, Inc. Reports Third Quarter 2026 Results

      Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric,...

      More Releases From This Source

      Explore

      Banking & Financial Services

      Banking & Financial Services

      Health Care & Hospitals

      Health Care & Hospitals

      Computer & Electronics

      Computer & Electronics

      Artificial Intelligence

      Artificial Intelligence

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.